Argitalpenak (48) MARÍA DEL CARMEN HERNÁNDEZ VALLADARES argitalpenak

2024

  1. High Mitochondrial Protein Expression as a Potential Predictor of Relapse Risk in Acute Myeloid Leukemia Patients with the Monocytic FAB Subtypes M4 and M5

    Cancers, Vol. 16, Núm. 1

2023

  1. La proteómica mediante espectrometría de masas como metodología esencial en estudios clínicos

    Educación hacia el futuro: enfoque STEAM, ciencias de la salud y deporte (Dykinson), pp. 557-576

  2. Mass Spectrometry-Based Proteomics Workflows in Cancer Research: The Relevance of Choosing the Right Steps

    Cancers, Vol. 15, Núm. 2

  3. Multi-Omic Approaches to Classify, Predict, and Treat Acute Leukemias

    Cancers

  4. Special Issue “Personal Therapy for Blood Disorders”

    Journal of Personalized Medicine

  5. Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity

    Journal of Clinical Medicine, Vol. 12, Núm. 17

2022

  1. A developmental role for the chromatin-regulating CoREST complex in the cnidarian Nematostella vectensis

    BMC Biology, Vol. 20, Núm. 1

  2. Comparing Efficiency of Lysis Buffer Solutions and Sample Preparation Methods for Liquid Chromatography–Mass Spectrometry Analysis of Human Cells and Plasma

    Molecules, Vol. 27, Núm. 11

  3. Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia

    Expert Review of Proteomics

2021

  1. Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  2. Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells

    DISEASES, Vol. 9, Núm. 4

  3. Proteomic comparison of bone marrow derived osteoblasts and mesenchymal stem cells

    International Journal of Molecular Sciences, Vol. 22, Núm. 11

  4. Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatment based on all-trans retinoic acid and valproic acid

    Cancers, Vol. 13, Núm. 9

  5. Therapeutic use of valproic acid and all-trans retinoic acid in acute myeloid leukemia—literature review and discussion of possible use in relapse after allogeneic stem cell transplantation

    Pharmaceuticals, Vol. 14, Núm. 5

2020

  1. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation

    Aging, Vol. 12, Núm. 24, pp. 24734-24777

  2. Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia

    Cancers, Vol. 12, Núm. 3

  3. The implementation of mass spectrometry-based proteomics workflows in clinical routines of acute myeloid leukemia: Applicability and perspectives

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-23

  4. The progression of acute myeloid leukemia from first diagnosis to chemoresistant relapse: A comparison of proteomic and phosphoproteomic profiles

    Cancers, Vol. 12, Núm. 6, pp. 1-13

2019

  1. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells

    Signal Transduction and Targeted Therapy, Vol. 4, Núm. 1

  2. Protein post-translational modification crosstalk in acute myeloid leukemia calls for action

    Current Medicinal Chemistry, Vol. 26, Núm. 28, pp. 5317-5337